Chief Scientific Officer
Stephane Milano is serving WIL Research as Chief Scientific Officer (Europe). He is providing strategic scientific leadership for European operations as appropriate to the Executive Management Team of WIL Research Company. As part of his responsibilities, Stephane Milano is responsible for developing the Safety Pharmacology and Discovery Services in Europe.
He has over 15 years of experience in the areas of pharmacology and physiology and has authored over 50 scientific papers and abstracts. He also has filed two patents on the use of recombinant gastric lipase for treating functional dyspepsia and Modified PAR receptors for selecting compounds. Dr. Stéphane Milano is an active member of the Safety Pharmacology Society since 2003.
He participated to NOTOCORD Usergroups 2012 and 2014.
Watch below his testimonial on the NOTOCORD Usergroups.